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Abstract: Approximately 20%–25% of all breast cancers over express a key cell surface growth factor receptor known as HER2. HER2 
plays a key role in cell growth and proliferation and is linked to worse clinical outcomes, making it a logical therapeutic target. The first 
HER2 targeted drug to be approved by the FDA, was the humanized monoclonal antibody trastuzumab, after it showed improvements 
in survival in the adjuvant setting, and delayed time to progression in the metastatic setting. Although highly effective, for reasons that 
are not clear, some patients display resistance to trastuzumab. Lapatinib is an oral, small molecule tyrosine kinase inhibitor, that inhibits 
both the HER1 ahd HER2 receptors and may be able to overcome trastuzumab resistance. Lapatinib is approved in the second line set-
ting for use in combination with capecitabine or with letrozole. In this review, we will discuss the indications, concerns or any issues 
with regards to the drug.
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Introduction
Breast cancer is the commonest form of cancer in 
women worldwide and second leading cause of cancer-
related death in North American women.1 Although 
treatment with chemotherapy, endocrine therapy and 
targeted therapy has significantly improved outcomes 
for women with early stage disease, overall survival 
for women with metastatic disease (MBC) remains 
poor with a five year survival rate of only 15% under-
scoring the need for novel therapeutic strategies.2
One of the major advances in the field of breast 
cancer has been the discovery that 20%–25% of breast 
cancers over express a key growth factor receptor 
known as the human epidermal growth factor recep-
tor 2 or HER2.3,4 The main function of HER2 is to 
mediate cell growth, differentiation, and survival and 
as a result, tumors over expressing the HER2 recep-
tor are more aggressive and have a poorer overall 
prognosis.5,6 HER2 belongs to a family of 4 closely 
related  receptor  tyrosine  kinases:  HER1  (EGFR, 
ErbB1), HER2 (ErbB2), HER3 (ErbB3) and HER4 
(ErbB4) (Fig. 1). These receptors generally have an 
N-terminus extra cellular ligand binding domain and 
a  C-terminus  cytoplasmic  domain  which  exhibits 
tyrosine  kinase  activity.  The  HER2  receptor  how-
ever has no known activating ligands and may be in 
a constitutively activated state or may only become 
active  upon  heterodimerization  with  other  family 
members such as EGFR. Upon ligand binding the 
HER   receptors homo- or hetero-dimerize with other 
members  of  the  family. This  stimulates  the  intrin-
sic intracellular tyrosine kinase activity,   resulting in 
auto phosphorylation and activation of downstream 
signal  transduction  pathways  such  as  the  mitogen 
activated protein kinase (MAPK) p  athway, and the 
phosphoinositide-3 kinase (PI3K)/Akt pathway. Acti-
vation of these pathways promotes cell proliferation, 
migration, angiogenesis and inhibition of apoptosis 
(Fig. 2).7,8 Therapeutic approaches, including mono-
clonal antibodies that interfere with ligand binding or 
receptor dimerization; and small molecules tyrosine 
kinase  inhibitors  (TKI)  which  block  downstream 
signaling have all been shown to effectively inhbit 
the tumor proliferating effects of the HER receptors. 
Emerging evidence suggests that targeting the HER 
receptor  by  different  approaches  concurrently  may 
even have additive antitumor effects.
Trastuzumab was the first HER2 targeted agent to 
enter clinical practice. It is an intravenously admin-
istered highly selective monoclonal antibody which 
targets the extra cellular domain of the HER2 recep-
tor  and  has  both  preclinical  and  clinical  antitumor 
activity. Trastuzumab was approved by the Food and 
Drug  Administration  (FDA)  in  1998  after  a  land-
mark  Phase  III  study  showed  significant  improve-
ment in response and survival when added to first 
line chemotherapy for the treatment of patients with 
HER2+ MBC.9 Trastuzumab is now also approved in 
the adjuvant setting after four large multicenter ran-
domized trials (NSABP B-31, NCCTG N9831, HERA 
and BCIRG 006) showed significant improvements 
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Figure 2. The Neo-Adjuvant Lapatinib and/or Trastuzumab Treatment 
Organization  (Neo-ALTTO)  study  is  a  randomized,  multicentre  open-
label  phase  iii  study  of  neoadjuvant  lapatinib,  trastuzumab  and  their 
combination plus paclitaxel in women with HeR2/erbB2 positive primary 
breast cancer.
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Figure 1. Human epidermal growth factor receptor family and   targeted 
therapy.Lapatinib in breast cancer
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in disease free survival (DFS) and overall survival 
(OS) when trastuzumab was combined with chemo-
therapy.10–13 Use of trastuzumab in HER2+ breast can-
cer is now standard of care both in the adjuvant and 
metastatic settings. Despite over expression of HER2, 
some  patients  display  primary  or  acquired  trastu-
zumab resistance for reasons that are not completely 
understood. Several mechansims of resistance have 
been proposed including the presence of a truncated 
HER2 receptor known as p95HER2 which lacks an 
extra cellular binding domain and is not only resistant 
to trastuzumab but may also be a predictor of worse 
outcome.14 Other mechanisms of resistance include 
up regulation and cross talk between pathways down-
stream of HER2 such as the Insulin-like growth fac-
tor (IGF-1) pathway;15 or deficiency of a key tumor 
suppressor gene known as PTEN which regulates the 
PI3K/Akt pathway or similarly activating mutations 
within  the  p110-alpha  subunit  of  PI3Kinase;16,17  or 
failure of antibody   activity. Nonetheless, at the clini-
cal level, trastuzumab resistance remains a significant 
challenge. Research is ongoing to discover and develop 
novel HER2 targeted therapies that can overcome this 
resistance and slow or stop disease progression.
Lapatinib
Lapatinib  ditosylate  (GW  572016; Tykerb,  Glaxo 
Smith  Kline)  monohydrate  is  an  oral  small  mol-
ecule  derivative  of  4-anilinoquinazoline  which 
targets  the  C-terminus  tyrosine  kinase  domain  of 
both  the  HER2  and  EGFR  receptors.  Lapatinib 
  reversibly attaches to and competes with ATP for 
binding to the   intracellular adenosine triphosphate 
(ATP)  binding  site  of  the    receptor.  This  inhibits 
both phosphorylation and activation of the down-
stream  Ras-Raf-  mitogen-activated  protein  kinase 
and PI3K-Akt signaling cascades resulting in cell 
cycle  arrest,  and  increased  apoptotic  activity.18 
  Lapatinib is considered a potent inhibitor because of 
its slow dissociation half life of .300 minutes caus-
ing longer inhibition of the receptors compared to 
other EGFR targeting quinazolines such as erlotinib 
(Tarceva) and gefitinib (Iressa), used commonly in 
the management of lung cancer.19 In BT474 HER2 
over expressing breast cancer cell lines, lapatinib 
decreases  HER2  and  EGFR  phosphorylation  and 
blocks  activation  of  the  downstream  ERK  (extra 
cellular signal related kinase) and Akt pathways in 
a time and dose-  dependent manner.20 Lapatinib also 
shows  activity  against  trastuzumab-  resistant  cell 
lines where it decreased phosphorylation and acti-
vation of IGF-1 and s6 kinase-two pathways that 
may mediate trastuzumab resistance.21,22 Combining 
lapatinib and trastuzumab in HER2 over express-
ing cell lines, has further demonstrated additive or 
synergistic effects, which have now also been con-
firmed in the clinical setting. Studies are also ongo-
ing to b  etter understand what factors may predict 
for sensitivity or resistance to lapatinib. Resistance 
mechanisms including increased signalling via estro-
gen   receptors, mutations within the HER2 receptor, 
hyper activation and PIK3Ca mutations of the PI3K 
pathway and over expression of other key receptors 
have been proposed.23–25
Clinically Lapatinib has now been evaluated in a 
number of studies and was approved by the FDA for 
use with capecitabine for HER2+ MBC, pretreated with 
prior anthracycline, taxane, and trastuzumab-contain-
ing regimens. In 2010, Lapatinib was also approved for 
use with letrozole for HER2+, hormone receptor posi-
tive MBC. In this review, we will focus on the clinical 
evaluation of lapatinib in terms of its efficacy and toler-
ability and will also discuss future directions.
Clinical Studies
Phase 1 and safety studies  
with lapatinib monotherapy
Two phase 1 studies were conducted to determine the 
safety, tolerability and pharmacokinetics of lapatinib 
administered as single and multiple dosing in healthy 
individuals.  No  serious  adverse  events  were  noted 
with  either  dosing  schedule.26  The  most  common 
adverse events (AE) were headache, diarrhea, rash, 
cold symptoms, gastrointestinal symptoms, and ele-
vated liver function tests. In a dose escalation study 
of 67 heavily pretreated patients with HER2 and/or 
HER1 over expressing metastatic cancers, Lapatinib 
was well tolerated at doses up to 1600 mg daily with 
clinical activity seen from 650–1600 mg daily, but 
most  commonly  between  900–1200  mg. At  doses 
where clinical activity was observed, the main tox-
icities were grade 1 and 2 diarrhea (42%) and skin 
rash (31%). No grade 4 toxicities were reported and 
there was no cardiac toxicity. Diarrhea was linearly 
related to dose over the 500–1600 mg range, but not Sridhar and Rana
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serum drug concentration, suggesting that Lapatinib 
may have direct toxic effects on the gut epithelium. 
Rash has been recognized as a common side effect 
of HER1 targeting agents, and has been proposed as 
a surrogate marker of efficacy; however this has not 
been confirmed and in this study there was no cor-
relation between rash and efficacy. Pharmacokinetic 
studies showed peak serum concentrations occurred 
at a median of 3 hours after dose, and steady state 
levels were achieved at 6–7 days. Lapatinib is metab-
olized hepatically via CYP3A4 requiring dose reduc-
tions with hepatic dysfunction and dose modifications 
when used with other CYP3A4 A inducers/inhibitors 
such as antibiotics and antiepileptics. This dose esca-
lation study was the first to show clinical activity of 
lapatinib. Four HER2+ trastuzumab pretreated MBC 
patients  showed  partial  responses  (PR)  of  median 
duration of 5.5 months and 10 other HER2+ MBC 
pts showed stable disease for .6 months at a dose of 
1200 mg daily.27
Another Phase 1 study involved 33 HER2 and/or 
EGFR over expressing metastatic cancers treated with 
Lapatinib. Four MBC pts had PRs and 11 pts with 
other  cancers  had  stable  disease  (SD).  Correlative 
studies showed responders had variable levels of inhi-
bition of p-ErbB1, p-ErbB2, p-Erk 1/2, p-Akt, cyclin 
D1, transforming growth factor alpha (TGFalpha), and 
as well as increased tumor cell apoptosis. Increased 
pretreatment expression of ErbB2, p-ErbB2, Erk 1/2, 
p-Erk 1/2, Insulin like growth factor 1 (IGF-1), p70 
S6 kinase, and TGFalpha all appeared to predict for 
clinical response, but this study was limited due to 
small sample size and therefore considered hypothesis 
  generating.28 However, the concept of doing   correlative 
studies to understand response or resistance to lapa-
tinib will be critical to moving the field forwards and 
should be incorporated into all trials where possible.
Phase II Studies with Single Agent 
Lapatinib
Lapatinib monotherapy, 1500 mg/day, was studied in 
an open-label Phase II study in HER2+ (n = 140) and 
HER2- (n = 89) heavily pretreated MBC patients. The 
HER2+ group was defined as 3+ HER2 by immuno-
histochemistry (IHC), or 2+ by IHC and HER2 ampli-
fied  by  fluorescence  in  situ  hybridization  (FISH). 
The HER2+ group had a response rate by independent 
review of 1.4% and a clinical   benefit rate (CBR) of 
5.7%, where CBR was defined as (complete response 
(CR)  +  PR  +  SD  for    24  wks).  There  were  no 
responses in the HER2- group. Time to progression 
(TTP) was 9.1 wks (HER2+) vs. 7.6 wks (HER2-) 
and median survival (MS) was 29.4 wks vs. 18.6 wks 
respectively. Consistent with previous lapatinib stud-
ies, the most common AEs were diarrhea (59%), nau-
sea (37%), and rash (32%).29
In another phase II study, 78 HER2+ MBC pts 
who had up to 2 prior trastuzumab containing regi-
mens received lapatinib 1250 or 1500 mg once daily. 
Response  rate  was  5.1%,  CBR  was  9.0%,  median 
TTP was 15.3 wks, and MS was 79 wks. The results 
of  this  study  were  likely  better  than  the  Burstein 
study due to the limitation on number of prior lines of 
therapy. Toxicities were similar (rash, diarrhea, nau-
sea) and both doses of lapatinib were well tolerated.30 
Given these encouraging phase II results with respect 
to both efficacy and tolerabilty, further combination 
studies with lapatinib were undertaken.
Combination of Lapatinib and 
Chemotherapy
In MBC the taxanes which stabilize microtubules are 
amongst the most active and frequently used agents. 
Combining the taxanes with trastuzumab in HER2+ 
disease has previously been shown to be effective and 
is standard first line treatment. In the seminal report 
by Slamon et al the addition of trastuzumab to chemo-
therapy increased response rates, prolonged duration 
of remissions, and lengthened survival vs. chemo-
therapy alone.9 Trastuzumab has also been combined 
effectively with other chemotherapy regimens, pro-
viding the basis for similar combination studies of 
lapatinib and chemotherapy.
Lapatinib and Paclitaxel
After a phase II study showed efficacy and tolerability 
of combining lapatinib and paclitaxel, a phase III dou-
ble blind study of 579 HER2- and HER2 uncharacter-
ized MBC pts was conducted. Patients received either 
paclitaxel (175 mg/m2 IV q3 wks) or the c  ombination 
of paclitaxel and lapatinib 1500 mg daily. This trial was 
important because it served to demonstrate the impor-
tance of HER2 status in dictating response to   Lapatinib. 
After central   pathology review, 15% of pts who were 
confirmed  to  be  HER2+  had  a  statistically  higher 
objective  response  rate  (60%  vs.  36%,  P =  0.027), Lapatinib in breast cancer
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and better TTP (8.1 vs. 5.8 mo, P = 0.011) with the 
combination compared with paclitaxel alone. HER2-
patients on the other hand, did not benefit from the 
addition of lapatinib. Toxicity in the combination arm 
was significantly higher with rash, diarrhea, mucositis, 
vomiting and more fatal AE related to sepsis and diar-
rhea, the latter necessitating aggressive antidiarrheal 
management.31 In light of these results, a head to head 
trial in the first line setting comparing paclitaxel with 
lapatinib vs. paclitaxel with trastuzumab in first line 
HER2+ MBC was initiated. Correlative studies includ-
ing  pharmacogenomics  and  pharmacokinetics  may 
add important information about what host and drug 
factors may impact on both toxicity and response to 
these regimens.
Lapatinib and Capecitabine
For  patients  progressing  on  the  taxanes,  sec-
ond  line  treatment  often  consists  of  capecitabine, 
an  oral  prodrug  of  the  DNA  synthesis  inhibitor 
5-  fluoruracil. A Phase I study of 45 pts combining 
lapatinib (1250 mg) with capecitabine (2000 mg/m2) 
given on days 1–14, showed, an AE profile to be 
no worse than either drug alone, and evidence of 
antitumor    activity.32  This  led  to  the  pivotal  ran-
domized phase III study of 324 patients comparing 
lapatinib plus capecitabine vs. capecitabine alone.33 
Unlike  the  prior    paclitaxel  +  lapatinib  study,  eli-
gible patients had to have HER2+ (3+ by IHC, or 
2+ by IHC+ and FISH+) MBC progressing after an 
anthracycline, a taxane, and trastuzumab. Prior treat-
ment with capecitabine was not permitted, but fluo-
rouracil was allowed. Normal LVEF was required 
and central nervous system (CNS) metastases were 
permitted if clinically stable for at least 3 months 
after the discontinuation of corticosteroid and anti-
convulsant therapy. The interim analysis showed the 
median TTP was 8.4 mo (combination) vs. 4.4 mo 
(mono therapy), representing a 51% reduction in the 
risk of disease progression (P , 0.001). The Objec-
tive response rate was 22% vs. 14%, which was sta-
tistically significant. Biomarker analysis confirmed 
that FISH confirmation of IHC HER2 positivity most 
accurately predicted for response to the   combination. 
The main AE in the combination arm were diarrhea, 
hand-foot  syndrome,  nausea,  vomiting,  fatigue, 
and  rash.33  On  the  basis  of  efficacy  and  absence 
of safety concerns, the data safety and monitoring 
committee  recommended  terminating  enrollment, 
reporting  the  results,  unblinding,  and  allowing  36 
patients to cross over to receive lapatinib. Final analy-
sis supported the TTP benefit and this trial ultimately 
led to the FDA approval of lapatinib plus capecit-
abine in trastuzumab resistant HER2+ MBC.34 Lapa-
tinib plus capecitabine is currently under evaluation 
as first line therapy in HER2+ MBC. Another key 
finding of this study was the reduction of CNS metas-
tases as first site of disease progression in patients 
receiving lapatinib. Unlike trastuzumab, lapatinib is 
a small molecule and as such may be able to pen-
etrate the blood brain barrier better in the context 
of CNS metastases. As will be discussed, dedicated 
trials with Lapatinib are underway focusing on the 
issue of CNS metastases.
Lapatinib and Vinorelbine
For  patients  progressing  on  a  taxane  and  capecit-
abine, vinorelbine (a vinca alkaloid) represents a well 
tolerated  IV  chemotherapy  option  administered  on 
days 1 and 8 of a 21 days cycle. Efficacy and safety 
of   Lapatinib with vinorelbine, in patients previously 
treated with taxanes and/or anthracyclines has recently 
been reported. Lapatinib 1250 mg daily, and Vinorel-
bine 25 mg/m2 was used in the first 6 patients but then 
reduced to Vinorelbine 20 mg/m2 after neutropenia 
was a found to be an issue. PRs were seen in 5/19 
patients, SD in 8/19, and progression free survival 
(PFS) was 20 wks in a patient population who had a 
median 2 (range 1–4) prior chemotherapy regimens.35 
Lapatinib plus Vinorelbine, is also being evaluated 
in earlier stage metastatic disease, and in one study 
being compared with lapatinib and capecitabine with 
an optional cross over at progression.36
Lapatinib and Gemcitabine/Cisplatin
Lapatinib plus the two drug regimen of Gemcitabine 
and  Cisplatin  has  also  been  evaluated.  In  a  phase 
1 study, pretreated HER2+ MBC patients received 
Gemcitabine 1000 mg/m2 IV days 1 and 8, Cisplatin 
25 mg/m2 days 1 and 8 and oral lapatinib 1000 mg 
continuously. In this small study of 19 patients Grade 
3 or 4 hematologic toxicity, diarrhea, hepatic toxic-
ity and mucositis were observed. Median PFS was 
4 months, and CBR was 44%, suggesting that this 
may be an active regimen, but dosing may not be 
optimal for this heavily pretreated population.37Sridhar and Rana
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Lapatinib and other 2 or 3 Drug 
Combinations
There are several other studies of lapatinib in com-
bination with 2 or 3 drug chemotherapy regimens. 
As illustrated above, the main consideration of these 
multidrug regimens may be one of tolerability, and so 
the best setting in which to evaluate these combina-
tions may be in early stage disease where patients are 
less heavily pretreated.
The GeparQuinto was an open-label Phase III 
trial led by the German Breast Group evaluating 
620  HER2+  patients  in  the  neoadjuvant  setting. 
Patients  received  epirubicin/cyclophosphamide 
(EC)  followed  by  docetaxel  in  combination  with 
either trastuzumab or lapatinib. Postoperatively, the 
trastuzumab group received an additional 6 months 
of trastuzumab while the lapatinib group received 
trastuzumab for 12 months. The primary endpoint 
was  pathological  complete  (pCR)  defined  as  the 
no invasive or noninvasive residual disease in the 
breast and nodes. In the trastuzumab arm pCR was 
31.3% vs. 21.7% in the lapatinib arm (P , 0.03). 
Most common adverse events were gastrointesti-
nal,  blood  disorders  and  infections.  Discontinua-
tion and dose reductions due to toxicity were more 
common in the lapatinib arm raising the question 
of  whether  this  may  have  impacted  on  efficacy. 
Analysis of primary endpoint efficacy and safety 
findings is ongoing.38 Other early studies include 
a  preoperative  lapatinib  +  paclitaxel  +  gemcit-
abine  study.  This  regimen  was  well  tolerated  so 
there are now plans for a Phase 2.39 Another Phase 
1 study of   Lapatinib plus Docetaxel, Carboplatin 
and T  rastuzumab (TCarboH) in the adjuvant setting 
required   Lapatinib dose reductions to 750 mg/day 
due to diarrhea, highlighting the fact that in chemo-
therapy c  ombinations with lapatinib, diarrhea may 
be a dose   limiting toxicity.40
Lapatinib and Hormonal Therapy
There is now a growing body of evidence to suggest 
that  cross-talk  exists  between  HER2  and  estrogen 
receptors,  and  this  cross  talk  may  underlie  trastu-
zumab resistance and provides the rationale for com-
bining lapatinib with hormonal therapy. As an added 
benefit, both Lapatinib and hormonal therapy are oral, 
well tolerated, and have few overlapping toxicities.
Lapatinib in combination the aromatase inhibitor, 
letrozole, has been evaluated in a Phase I trial with 
39 patients with hormone receptor positive MBC.41 
Clinically relevant doses of lapatinib in   combination 
with letrozole were well tolerated and did not result 
in pharmacokinetic interaction. In a phase III trial, 
postmenopausal women with hormone receptor posi-
tive MBC were randomized to lapatinib 1500 mg 
daily plus letrozole 2.5 mg daily or letrozole alone.42 
In 219 HER2+ pts median PFS was 8.2 months in 
the letrozole-lapatinib group versus 3.0 months in 
the letrozole alone group (HR 0.71). CBR was sig-
nificantly higher for the combination group 48% vs. 
29% for letrozole alone. There was no improvement 
in PFS seen in the HER2- patients. In the combi-
nation arm, grade 3/4 diarrhea and rash were more 
  common.  Lapatinib  is  currently  being  tested  in  2 
phase II   trials, in hormone resistant, estrogen recep-
tor positive MBC, both as a single agent, and in com-
bination with tamoxifen.
Lapatinib and Targeted Therapy
Lapatinib and trastuzumab
Perhaps one of the most exciting areas of drug devel-
opment is the concept of combining targeted therapies 
without the need for chemotherapy. Several preclini-
cal studies have shown that dual HER2 targeting, with 
lapatinib plus trastuzumab has a synergistic antitumor 
effect. In a phase 1 study of 54 pts, lapatinib plus tras-
tuzumab was well tolerated at a dose of lapatinib of 
1000 mg/day and weekly trastuzumab.43 This led to 
a Phase III study, in HER2+, MBC patients failing 
prior trastuzumab. There were 296 pts randomized to 
lapatinib plus trastuzumab or lapatinib alone. Despite 
being heavily pretreated and having disease progres-
sion on prior trastuzumab, the combination arm had 
improved PFS (HR 0.73) and CBR (24% vs. 12.4%) 
compared  with  lapatinib  alone.  There  was  also  a 
nonsignificant trend towards improved OS with the 
combination. The results of this study confirm the pre-
clinical anti-tumor benefits of a more complete HER2 
blockade and offer a non-chemotherapy containing 
treatment option. The commonest AE in the combina-
tion were fatigue with diarrhea, and cardiac toxicity 
was no worse than each agent alone.44 In a separate 
study assessing the quality of life (QOL), which is a 
critical endpoint in studies of advanced disease, the Lapatinib in breast cancer
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QOL with the combination was comparable to Lapa-
tinib alone.45 The encouraging results of these studies 
have led to the combination of lapatinib and trastu-
zumab being evaluated in both the neoadjuvant and 
adjuvant settings.
In  the  neoadjuvant  setting  the  landmark 
NeoALTTO study randomized patients to lapatinib, 
trastuzumab or the combination of lapatinib plus tras-
tuzumab for six weeks, followed by the same treat-
ment plus paclitaxel for an additional 12 weeks until 
surgery (Fig. 3).46 The primary endpoint was patho-
logical complete response (pCR) defined as no inva-
sive cancer in the breast or only noninvasive in-situ 
cancer. Secondary endpoints included pCR in breast 
and lymph nodes (total pCR); objective response rate 
at week 6,% of patients with node-negative disease 
at surgery, rate of conversion to breast conserving 
surgery in all patients and in those with nonoperable 
disease at presentation, disease free survival (DFS) 
overall survival (OS) and safety and tolerability. The 
pCR rate was significantly higher (51.3%) for the 
combination compared to trastuzumab alone (29.5%) 
vs. lapatinib alone (24.7%). In terms of total pCR, 
again dual HER2 therapy appeared superior, with a 
trend towards better response in hormone receptor 
negative pts. Manageable toxicities, primarily diar-
rhea  and  liver  enzyme  alterations  were  increased 
in both lapatinib containing arms, and again there 
were no major cardiac toxicities. Overall this study 
supports preclinical results showing benefit of dual 
HER2 blockade. As well it illustrates the advantages 
of evaluating new agents in the neoadjuvant setting 
where there is potential for evaluating not only clini-
cal response but also biological responses and poten-
tially adding imaging correlates. The results of this 
study, are potentially practice changing, but raise a 
key question about the cost of using two targeted 
agents concurrently.
In the adjuvant setting, the ALTTO trial (Adjuvant 
Lapatinib and/or Trastuzumab Treatment Optimiza-
tion) randomized early stage HER2+ pts to one of 4 
treatment arms: trastuzumab alone for 52 wks, Lapa-
tinib alone for 52 wks, trastuzumab for 12 or 18 wks, 
followed by a 6 wk break, followed by lapatinib for 
28 or 34 wks, or lapatinib in combination with tras-
tuzumab for 52 wks. The primary objective was to 
compare DFS between each of the lapatinib contain-
ing arms and trastuzumab alone. Secondary objec-
tives included OS, time to recurrence, time to distant 
recurrence, safety and tolerability and incidence of 
brain metastasis. Each of these analyses would be 
conducted  according  to  cmyc  gene  amplification, 
expression of PTEN, and p95HER2 domain. After an 
interim analysis, the lapatinib alone arm was discon-
tinued because it was felt that it was unlikely to meet 
the pre-specified criteria to demonstrate noninferior-
ity to trastuzumab in DFS. The trial has now closed to 
accrual with final results pending.
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Lapatinib and Angiogenesis 
Inhibitors, mTOR Inhibitors
In  two  separate  studies,  Lapatinib  has  also  been 
evaluated in combination with pazopanib, a vascular 
endothelial growth factor receptor (VEGFR) tyrosine 
kinase  inhibitor  and  Bevacizumab,  an  antibody  to 
VEGF respectively. In both studies toxicity was man-
ageable and early clinical activity was seen. Building 
on this and the studies above, a triplet combination of 
lapatinib, trastuzumab and bevacizumab was under-
taken. Again, there were no major toxicities and pre-
liminary responses were seen in MBC resistant to 
both trastuzumab and lapatinib.47 Other combination 
strategies include lapatinib and the mTOR inhibitor 
everolimus. The mTOR pathway may play a role in 
trastuzumab  resistance  providing  the  rationale  for 
this approach. Diarrhea, stomatitis and fatigue were 
the main dose limiting toxicities of this combination 
and the maximal tolerated dose was determined to 
be 1250 mg lapatinib, and 5 mg everolimus daily.48 
Taken  together,  the  encouraging  results  seen  with 
these studies combining HER2   targeted therapies with 
other targets increases hope that non- chemotherapy 
containing regimens may prove to be both well toler-
ated and active in advanced disease.
Lapatinib and Brain Metastases
As mentioned, there is also interest in the role of lapa-
tinib in managing CNS metastases. Due to its small 
size, lapatinib can theoretically cross the blood brain 
barrier  whereas  the  larger  trastuzumab  molecule 
cannot. Although pre-clinical models did not show 
lapatinib crossed the intact blood-brain barrier to a 
significant  degree,  the  blood-brain  barrier  may  be 
more permissive in the setting of metastases.1
Lapatinib  monotherapy  was  evaluated  in  a 
Phase  II  study  of  39  HER2+  trastuzumab  pre-
treated patients, with refractory brain metastases.49 
One patient achieved a PR in the brain by RECIST 
(Response Evaluation Criteria in Solid Tumors) cri-
teria and seven patients (18%) were progression free 
in both the CNS and non-CNS sites at 16 weeks. The 
most common AEs were diarrhea and fatigue. Brain 
metastases were also examined in another Phase II 
trial with pts who had CNS progression after cranial 
radiation.50  Objective  responses  were  observed  in 
6% of 242 patients in the lapatinib group and in 20% 
of patients who received lapatinib and c  apecitabine. 
This study confirmed the modest antitumor activity 
of lapatinib and the additional response when com-
bined  with  capecitabine.  Another  similar  study 
showed the benefit of capecitabine and lapatinib in 
81 HER2+ patients with brain metastases who were 
not pretreated with either lapatinib or capecitabine.51 
Patients treated with lapatinib and capecitabine had a 
median overall survival benefit compared to patients 
treated with trastuzumab based therapies only, beyond 
brain progression (27.9 months versus 16.7 months 
respectively, P = 0.01). In the Landscape Phase II 
trial,  HER2+  MBC  patients  with  brain  metastases 
before whole-brain radiotherapy were treated with 
lapatinib 1250 mg/day and capecitabine 2000 mg/m2. 
The CNS-OR rate was 67% (95% CI 51–81), with a 
median time from inclusion to response of 1.8 month. 
Median  TTP  was  5.5  months  (95%  CI  3.9–5.9) 
and  median  time  to  whole-brain  radiotherapy  was 
8.3  months  (95%  CI  5.1–11.7).  However,  grade 
3+  drug  related  toxicities  were  common,  suggest-
ing that dosing may need to be adjusted. Two com-
bination studies with lapatinib for CNS metastases 
are also underway. The first Phase 1 study combines 
lapatinib with the   chemotherapy temozolamide and 
early data shows good tolerability at all dose levels.52 
The   second Phase 1 study examined the combination 
of lapatinib and whole brain radiotherapy but did not 
meet its predefined criteria for feasibility and toxic-
ity was a concern.53 Nonetheless, the ability of Lapa-
tinib to penetrate the CNS offers an important step 
forwards, in a disease that can often be controlled 
well systemically but has a propensity for difficult to 
control CNS metastases.
Conclusions
There have been significant advances in the field of 
HER2+ breast cancer over the last decade, with sev-
eral new agents targeting the HER2 pathway, but other 
related pathways also now becoming available. After 
trastuzumab,  lapatinib,  a  small  molecule  tyrosine 
kinase inhibitor is the second HER2 targeted agent to 
be approved in HER2+ MBC: either in combination 
with capecitabine in second line or in combination 
with letrozole for hormone receptor positive disease. 
Unlike trastuzumab, lapatinib is oral, has less cardio-
toxicity and may penetrate the CNS better. Several 
studies are ongoing to examine the role of lapatinib 
in   additional settings including the n  eoadjuvant and Lapatinib in breast cancer
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  adjuvant   settings, in combination with other targeted 
agents including HER2 targeted agents as well as in 
the setting of CNS metastases. Perhaps most inter-
esting and exciting, is the confirmation of preclinical 
studies that targeting the HER2 receptor by differ-
ent approaches concurrently may be the most effec-
tive,  raising  the  potential  for  a  nonchemotherapy 
based treatment approach in breast cancer in the very 
near future.
In addition to lapatinib there are also a number 
of other molecular targeted agents being studied for 
use in breast cancer. Neratinib for example is an oral, 
irreversible pan-ErbB receptor TKI being evaluated 
in  both  early  stage  and  advanced  breast   cancer.54 
There  is  also  emerging  data  for  the  treatment  of 
  trastuzumab-refractory  disease  with  other  novel 
agents including pertuzumab (receptor dimerization 
inhibitor), trastuzumab-DM1 (trastuzumab linked to 
maytansine chemotherapy), HSP90 and P13K path-
way inhibitors.55
As more and more agents become available, fur-
ther research will be needed to determine how best 
to  sequence  these  agents  manage  toxicity  and  tai-
lor treatments to an individual patient. There is also 
the question of dosing, because unlike classic cyto-
toxic agents, it is not clear that higher dose neces-
sarily correlates with better efficacy. In the case of 
lapatinib, there is interest in the question of whether 
appearance  of  a  rash  correlates  with  efficacy  and 
whether it is appropriate to titrate dosing according to 
rash. As we aim to move forwards in the field obtain-
ing biopsies at the time of disease progression may 
need to be incorporated into the standard of care. This 
may result in a better understanding of the patterns of 
resistance and allow us to choose the most appropri-
ate subsequent treatment. It is without doubt an excit-
ing time in the field of HER2 positive breast cancer 
with two drugs already approved and several other 
novel agents currently in development in preclinical 
and clinical testing.
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